PDF herunterladen
Endosc Int Open 2014; 02(02): E96-E104
DOI: 10.1055/s-0034-1377182
Original article
© Georg Thieme Verlag KG Stuttgart · New York

Cost-effectiveness of colorectal cancer screening in Germany: current endoscopic and fecal testing strategies versus plasma methylated Septin 9 DNA[1]

Uri Ladabaum
1   Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
,
Lourdes Alvarez-Osorio
2   Boston Healthcare Associates International GmbH, Berlin, Germany
,
Thomas Rösch
3   Charité Medical University of Berlin, Virchow Clinic Campus, Berlin, Germany
,
Bernd Brueggenjuergen
2   Boston Healthcare Associates International GmbH, Berlin, Germany
4   Steinbeis University, Berlin, Germany
› Institutsangaben
Weitere Informationen

Publikationsverlauf

submitted 28. Februar 2014

accepted 17. März 2014

Publikationsdatum:
06. Juni 2014 (online)

Auch verfügbar auf
   Lizenzen und Reprints

Background and study aims: Colorectal cancer (CRC) screening strategies in Germany include guaiac-based fecal occult blood testing (gFOBT) starting at age 50 and a switch to colonoscopy at age 55 or continued gFOBT testing, but screening utilization is limited. Blood-based biomarkers, such as methylated Septin 9 DNA ( m SEPT9), may improve screening rates. We performed a cost-effectiveness analysis of current and emerging CRC screening strategies in Germany.

Methods: Using a validated Markov model, we compared annual gFOBT for ages 50 through 54 followed by biennial testing until age 75 (FOBT) or by colonoscopy at ages 55 and 65 (FOBT/COLO 55,65), substitution of fecal immunochemical testing (FIT) for gFOBT (FIT, FIT/COLO 55,65), and annual or biennial plasma m SEPT9 testing. We also considered persons who utilize only colonoscopy and varied age at colonoscopy utilization.

Results: The current strategies were more effective and less costly than no screening. FIT was more effective and less costly than m SEPT9 testing. FIT/COLO 55,65 cost €12 200 per quality-adjusted life-years gained in comparison with FIT. m SEPT9-based screening was cost-effective in comparison with no screening but was dominated by other cost-saving strategies. Differential screening utilization and adherence greatly affected incremental results between strategies. In probabilistic analyses, FIT was preferred in 49 % and FIT/COLO 55,65 in 47 % of iterations.

Conclusion: Currently available CRC screening strategies in Germany, including hybrid fecal testing/colonoscopy, are likely to be cost-saving. Current strategies appear superior to m SEPT9-based screening. The impact of blood-based biomarkers is likely to depend on utilization and adherence as much as on test performance characteristics and cost.

1 Contributorship: conception and design, U. L.; analysis and interpretation of data, U. L., L. A., B. B.; drafting the article or revising it critically for important intellectual content, U. L., L. A., T. R., B. B.; final approval of the version to be published, U. L., L. A., T. R., B. B.
Funding sources: unrestricted research grant from Abbott Molecular, Des Plaines, IL, USA. The sponsor had no role in the conduct of this study. No future research funding by the sponsor is pending for any author.


Appendix